The antibody backbone of T-DM1, trastuzumab (Herceptin®), which binds selectively to the extracellular domain of HER2 with a high affinity, was previously approved for the treatment of HER2-overexpressing breast cancer [17]. Here, ERBB2 is linked to breast cancer.